Iron Deficiency Anemia

Rajendra K Arumugam et al. (2025) · Advanced biomedical research

This open-label, randomized proof-of-concept trial protocol, from the Siddha Regional Research Institute in Puducherry, India, sets out to test Thiriloga Chendhuram (TC) — a herbometallic (herb-and-mineral) preparation from Siddha medicine, a traditional healing system from South India — against another Siddha remedy, Annabedhi Chendhuram (ABC), for treating iron deficiency anemia (called Veluppu Noi in Siddha terms) in women of reproductive age. Iron deficiency anemia is one of the most common nutritional deficiencies worldwide, and the conventional iron supplements used to treat it (governing red blood cell production) often cause stomach upset, part of why researchers are exploring gentler alternatives. The planned trial will randomly assign participants 1:1 to receive either TC or the active-comparator ABC, with clinical check-ins at days 4, 18, 33, and 49. Assessment blends classical Siddha diagnostic methods — examining body constitution, the body's three vital humors, and its seven bodily tissues — with modern blood testing, including a full hematology panel, iron studies, oxidative stress and antioxidant markers, and safety labs covering the liver, kidneys, and heart (via ECG). Because this publication is a trial protocol rather than a finished study, there are no outcome results to report yet (zero completed participants' data are described here). The authors state the trial was expected to finish roughly 12 months after publication, with results to follow separately. What the protocol does spell out clearly is how success will be measured: two markers singled out for their sensitivity in catching iron deficiency early — reticulocyte hemoglobin content (CHr, the iron content inside the newest red blood cells) and the percentage of hypochromic (pale, iron-poor) red cells — alongside a broad standard panel (serum ferritin, transferrin, erythropoietin, and markers of oxidative stress and antioxidant defenses). This groundwork is what will let a future analysis distinguish a genuine treatment effect from noise once the trial completes. The practical takeaway right now is limited: this is a promise of evidence, not evidence itself. Anyone considering TC for anemia today has no controlled outcome data to weigh, only the traditional-use rationale that motivated the study. Limitations to watch for once results appear include the open-label design (participants and clinicians will know their group assignment) and the small, single-center, proof-of-concept scale — both of which limit how confidently any eventual finding could generalize.